Local cell therapy using CCL19-expressing allogeneic mesenchymal stem cells exerts robust antitumor effects by accumulating CD103⁺ IL-12-producing dendritic cells and priming CD8⁺ T cells without involving draining lymph nodes.

ABSTRACT:

Background

Immune checkpoint blockade is a promising anticancer therapy, whereas the presence of T cells in tumor sites is indispensable for its therapeutic efficacy. To promote the infiltration of T cells and dendritic cells (DCs) into the tumor, we previously proposed a local cell therapy using chemokine (C-C motif) ligand 19 (CCL19)-expressing immortalized syngeneic immortalized mesenchymal stem cells (syn-iMSC/CCL19). However, the preparation of syngeneic/autologous MSC from individual hosts limits the clinical application of this cell therapy.

Methods

In this study, we further developed a new cell therapy using allogeneic iMSC/CCL19 (allo-iMSC/CCL19) using several tumor mice models.

Results

The allo-iMSC/CCL19 therapy exerted drastic antitumor effects, in which t

SUBMITTER: Iida Y 

PROVIDER: S-EPMC11647367 | biostudies-literature | 2024 Dec

REPOSITORIES: biostudies-literature